Ovarian Cancer | Specialty

The OncLive Ovarian Cancer condition center page is a comprehensive resource for clinical news and expert insights on ovarian cancer and evolving treatment approaches, including PARP inhibitors, antibody-drug conjugates, chemotherapy and more. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in ovarian cancer.

First‑in‑Class mRNA‑2416 Shows Tolerability, Biologic Activity in Ovarian Cancer and Other Advanced Solid Tumors

August 3rd 2025

mRNA‑2416, alone or with durvalumab, was well tolerated and biologically active in advanced solid tumors and ovarian cancer.

Geneva HRD Test Predicts Survival Benefit From Olaparib Plus Bevacizumab in Advanced Ovarian Cancer

July 31st 2025

The Geneva HRD test was predicitive for OS and PFS benefits with olaparib plus bevacizumab in advanced ovarian cancer.

Five Under 5: Top Oncology Videos for the Week of 7/13

July 20th 2025

The top 5 OncLive videos of the week cover insights in ovarian cancer, RCC, melanoma, non–small cell lung cancer, and non–muscle-invasive bladder cancer.

Dr Thaker on IMNN-001 Plus Neoadjuvant Chemo in Newly Diagnosed Ovarian Cancer

July 16th 2025

Premal H. Thaker, MD, MS, discusses data from a study of IMN-001 plus neoadjuvant chemotherapy in newly diagnosed epithelial ovarian cancer.

Relacorilant Plus Nab-Paclitaxel Provides PFS Benefit in Platinum-Resistant Ovarian Cancer

July 14th 2025

Alexander B. Olawaiye, MD, discusses key efficacy and safety findings from the ROSELLA trial and the future of relacorilant in platinum-resistant ovarian cancer.

FDA Receives NDA for Relacorilant in Platinum-Resistant Ovarian Cancer

July 14th 2025

The FDA has received an NDA for relacorilant for the treatment of patients with platinum-resistant ovarian cancer.

Five Under 5: Top Oncology Videos for the Week of 7/6

July 13th 2025

The top 5 OncLive videos of the week cover insights in ovarian cancer, RCC, melanoma, non–small cell lung cancer, and non–muscle-invasive bladder cancer.

Dr Lee on the Future Development of Rina-S in FRα+ Platinum-Resistant Ovarian Cancer

July 11th 2025

Elizabeth Lee, MD, discusses the future of Rina-S in FRα-expressing high-grade serous or endometrioid platinum-resistant ovarian cancer.

Dr Deng on the Effects of MSH6 on PARP Inhibitor Sensitivity in Ovarian Cancer

July 10th 2025

Ou Deng, PhD, discussed findings from a study investigating MSH6-modulated PARP inhibitor sensitivity in BRCA-proficient, high-grade serous ovarian cancer.

Dr Olawaiye on Phase 2 Data With Relacorilant and Nab-Paclitaxel in Ovarian Cancer

July 7th 2025

Alexander B. Olawaiye, MD, discusses data with relacorilant plus nab-paclitaxel in platinum-resistant ovarian cancer that led to the phase 3 ROSELLA trial.

PAOLA-1 Analysis Shows PD-L1 Expression Correlates With HRD Positivity in High-Grade Serous Ovarian Cancer

July 7th 2025

PD-L1 expression was more common in HRD-positive high-grade serous ovarian cancer, indicating potential prognostic value in newly diagnosed cases.

Perioperative IMNN-001 Utilizes Novel Delivery Route in Advanced Ovarian Cancer

July 1st 2025

Premal Thaker, MD, discusses findings for IMNN-001 plus perioperative chemotherapy in up-front, advanced ovarian cancer.

Dr Thaker on the Safety of IMNN-001 Plus Neoadjuvant Chemotherapy in Newly Diagnosed Ovarian Cancer

June 30th 2025

Premal H. Thaker, MD, MS, discusses the safety of intraperitoneal administration of IMNN-001 plus neoadjuvant chemotherapy in epithelial ovarian cancer.

Five Under 5: Top Oncology Videos for the Week of 6/22

June 29th 2025

The top 5 OncLive videos of the week cover insights in myelofibrosis, lung cancer, ovarian cancer, breast cancer, and melanoma.

Dr Olawaiye on Relacorilant Plus Nab-Paclitaxel in Platinum-Resistant Ovarian Cancer

June 25th 2025

Alexander B. Olawaiye, MD, discusses clinical implications of data from the phase 3 ROSELLA trial.

Final PICCOLO Data Underscore Mirvetuximab Soravtansine’s Efficacy in Later-Line Frα+ Platinum-Sensitive Ovarian Cancer

June 24th 2025

Mirvetuximab soravtansine continues to show efficacy and safety in final analysis of the phase 2 PICCOLO study.

Dr Thaker on Data for IMNN-001 Plus Neoadjuvant Chemotherapy in Newly Diagnosed Ovarian Cancer

June 23rd 2025

Premal H. Thaker, MD, discusses safety and efficacy data for IMNN-001 plus neoadjuvant chemotherapy in newly diagnosed ovarian cancer.

First-Line Rucaparib Maintenance Reduces Progression Risk Across Prognostic Subgroups in HRD– High-Grade Ovarian Cancer

June 22nd 2025

Rucaparib maintenance improved PFS in HRD-negative advanced ovarian cancer, irrespective of baseline prognostic factors.

Raludotatug Deruxtecan Shows Activity in Platinum-Sensitive Ovarian Cancer

June 21st 2025

Raludotatug deruxtecan showed promising clinical activity in patients with heavily pretreated, platinum-sensitive ovarian cancer.

Dr Graham on Advancements in the Management of Ovarian Cancer

June 13th 2025

Deena M. Atieh Graham, MD, discusses notable shifts within the ovarian cancer landscape leading to better patient outcomes.